Cladribine (2CdA) is a nucleoside analog that has been introduced as a promising agent for treatment of advanced SM but it does not counteract the kinase activity of C-KIT D816V or downstream signaling molecules (27). The gene discussed is KIT; the disease is systemic mastocytosis.